Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | CPA1 | P15085 | 2/20 | 0.34 |
| ▸ | MME | P08473 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7185803 | 0.82 | TP53 (0.40) | TP53CPA1MMERAB9AACE | |
| SCHEMBL7185807 | 0.82 | TP53 (0.40) | TP53CPA1MMERAB9AACE | |
| SCHEMBL4408919 | 0.80 | — | — | |
| SCHEMBL4408920 | 0.80 | — | — | |
| SCHEMBL28767303 | 0.76 | TP53 (0.35) | TP53CPA1MMERAB9AACE | |
| SCHEMBL23042930 | 0.74 | — | — | |
| SCHEMBL8518866 | 0.74 | SLC7A5 (0.33) | TP53CPA1MMERAB9AACE | |
| SCHEMBL28176802 | 0.72 | TP53 (0.32) | TP53 | |
| SCHEMBL23829541 | 0.72 | — | — | |
| SCHEMBL2807366 | 0.71 | TP53 (0.47) | TP53CPA1MMERAB9AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4591934-A2 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| WO-2025101863-A1 | CNP VARIANTS, CONJUGATES AND FORMULATIONS THEREOF | BIOMARIN PHARMACEUTICAL INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| EP-4523749-A2 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20230192799-A1 | CNP Variants and Conjugates Thereof | BIOMARIN PHARMACEUTICAL INC. | 2023-06-22 | — | — | US | disclosed |
| EP-4031183-A1 | CNP VARIANTS AND CONJUGATES THEREOF | BioMarin Pharmaceutical Inc. (US) | 2022-07-27 | — | — | EP | disclosed |
| EP-4029512-A1 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3175863-B1 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BIOMARIN PHARM INC (US) | 2021-12-01 | — | — | EP | disclosed |
| WO-2021055497-A1 | CNP VARIANTS AND CONJUGATES THEREOF | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-RE48267-E1 | Variants of C-type natriuretic peptide | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-RE46707-E1 | Variants of C-type natriuretic peptide | BIOMARIN PHARMACEUTICAL INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-7166574-B2 | Synthetic heparin-binding growth factor analogs | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20060205652-A1 | Formulations and methods for delivery of growth factor analogs | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. (US) | 2006-09-14 | — | — | US | disclosed |
| WO-2006093808-A1 | FORMULATIONS AND METHODS FOR DELIVERY OF GROWTH FACTOR ANALOGS | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060024347-A1 | Bioactive peptide coatings | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. (US) | 2006-02-02 | — | — | US | disclosed |
| WO-2006004868-A2 | BIOACTIVE PEPTIDE COATINGS | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20050222394-A1 | Dual chain synthetic heparin-binding growth factor analogs | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| EP-1539801-A2 | SYNTHETIC HEPARIN-BINDING GROWTH FACTOR ANALOGS | Biosurface Engineering Technologies, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040087505-A1 | Synthetic heparin-binding factor analogs | FERRING B.V. (NL) | 2004-05-06 | — | — | US | disclosed |
| WO-2004018499-A2 | SYNTHETIC HEPARIN-BINDING GROWTH FACTOR ANALOGS | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. (US) | 2004-03-04 | — | — | WO | disclosed |
| US-20040038348-A1 | Synthetic heparin-binding growth factor analogs | FERRING B.V. (NL) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205652-A1 | Formulations and methods for delivery of growth factor analogs | BMP1, BMP2, HDGF | TP53 1306/4885SLC1A3 2575/4885SLC1A2 3219/4885 |
| US-20040087505-A1 | Synthetic heparin-binding factor analogs | HDGF, HGF, FGF2 | TP53 2794/4885SLC1A3 2264/4885SLC1A2 2685/4885 |
| US-20230192799-A1 | CNP Variants and Conjugates Thereof | NPPA, NPR1, NPR3 | TP53 2244/4885SLC1A3 1269/4885SLC1A2 2039/4885 |
| US-20040038348-A1 | Synthetic heparin-binding growth factor analogs | HDGF, HGF, HDGFL3 | TP53 2027/4885SLC1A3 2989/4885SLC1A2 3777/4885 |
| US-20060024347-A1 | Bioactive peptide coatings | HDGF, FGF23, HGF | TP53 3815/4885SLC1A3 1835/4885SLC1A2 2309/4885 |
| US-20050222394-A1 | Dual chain synthetic heparin-binding growth factor analogs | HDGF, FGF2, HGF | TP53 2782/4885SLC1A3 2013/4885SLC1A2 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.